Government Payers

The 2025 social security financing bill includes measures to reduce spending on reimbursed drug costs, change the way that industry paybacks are calculated, and tackle medicine shortages.

A new UK medtech survey sets out industry’s market access and regulatory concerns and makes clear where system users see the need for improvement. There are some grounds for optimism, but the MHRA’s planned rise in regulatory fees could undo some of the good work.

The proposed CMS innovation center's $2 drug list model will not address the barriers to newer generics getting on Part D formularies and plans may have little incentive to participate in the demo, an industry group said.

The proposed CMS innovation center's $2 drug list model will not address the barriers to newer generics getting on Part D formularies and plans may have little incentive to participate in the demo, an industry group said. 

NHS England says it is proposing a “realistic but challenging uptake trajectory” that will make “this clinically and cost-effective drug” available to as many patients as possible without overwhelming health care providers.

The French pharma industry body Leem says that the scale of its contribution to health insurance cost savings is undermining the industry’s financial sustainability.

Texas comes out on top for biosimilar uptake, but how do the other US states compare? Geographical data can pinpoint which states are embracing biosimilars, and which have a way to go.   

Can the new UK government's raw enthusiasm for NHS reform be a catalyst for real change where countless past attempts to address the national provider's shortcomings have failed to hit the spot? And what might the 10-year plan mean for medtech?

Research published in the Annals of Internal Medicine finds the US time from a drug’s approval to reimbursement is not the swiftest, compared to countries in Europe.

As the US struggles to contain the cost of prescription medicines, a growing number of state governments are trying to take matters into their own hands and believe prescription drug affordability boards could be the answer.